Author + information
- J. Stephen Jones, MD, MBA∗ ()
- ↵∗Cleveland Clinic, Glickman Urological & Kidney Institute, 9500 Euclid Avenue, NA4, Cleveland, Ohio 44195
Risk calculators have become frequently used clinical tools. They are usually developed in research trial populations, but they are infrequently validated in real-world populations (1). This has been my experience (2) in prostate cancer diagnostics, so it is not surprising that a similar discrepancy has been found in the setting of cardiovascular risk prediction as identified in the study by Rana et al. (3). The investigators are to be congratulated on identifying this and interpreting the real-world ramifications of such a discrepancy. This study makes it clear that similar external validation in the target population is requisite to avoid misrepresenting clinical risk by real-world clinicians.
Please note: Dr. Jones has been a consultant for and received royalties from Healthtronics and Cook.
- 2016 American College of Cardiology Foundation